Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“AACR26 kicks off this week.
Breakthroughs will dominate the headlines: new targets, new molecules, early phase signals.
But the real question is different: who can actually deliver these therapies to patients?
From Australia, several programs reflect what this looks like in practice:
- CP-IVX oncolytic virus + sintilimab (Phase 1b) with ImmVirX.
- 4CAST seveterinol + chemotherapy in AR+ TNBC, exploring decentralised trial delivery Christine Chaffer Rachel Dear.
- Combination PDAC data with narmafotinib from Amplia Therapeutics, based on science developed at Garvan Institute of Medical Research.
We are generating more early phase signals than ever but most patients still never access them.
Australia’s edge isn’t just science. It’s networked trial delivery, biomarker integration, and cross-institution collaboration through initiatives like NSW Early Clinical Trials Alliance (NECTA).
If you’re working on early phase trials or translational biomarkers to support drug development, lets connect. I’ll be cochairing the Precision Oncology Mini-Symposium, Tuesday 21st April 2:30pm with Vivek Subbiah.”
Other articles featuring Jia Jenny Liu on OncoDaily.